Citations

Clear

4610 citation(s) found for "Lu, Brian".

Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma
Boddicker, Rebecca L., Razidlo, Gina L. , Dasari, Surendra , Zeng, Yu , Hu, Guangzhen , Knudson, Ryan A., Greipp, Patricia T. , Davila, Jaime , Johnson, Sarah H. , Porcher, Julie C., Smadbeck, James B. , Eckloff, Bruce W., Billadeau, Daniel D. , Kurtin, Paul J. , McNiven, Mark A. , Link, Brian K. , Ansell, Stephen M. , Asmann, Yan W. , Vasmatzis, George , Feldman, Andrew L. , Luchtel, Rebecca A. , Davila, Jaime I, Cerhan, James R. , Feldman, Andrew L , Link, Brian K , Razidlo, Gina L , Greipp, Patricia T , Davila, Jaime I

Mayo Clinic

Blood | June 14, 2016 | Volume: 128 | Issue: 9 | Pages: 1234-1245

10.1182/blood-2016-03-707141 | PMID 27297792 Get It

Abstract Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of T-cell malignancies that generally demonstrate aggressive clinical behavior, often are refractory to standard therapy, and remain significantly understudied. The most common World Health Organization subtype is PTCL, not otherwise specified (NOS), essentially a “wastebasket” category because of inadequate understanding to assign cases to a more specific diagnostic entity. Identification of novel fusion genes has contributed significantly to improving the classification, biologic understanding, and therapeutic targeting of PTCLs. Here, we integrated mate-pair DNA and RNA next-generation sequencing to identify chromosomal rearrangements encoding expressed fusion transcripts in PTCL, NOS. Two of 11 cases had novel fusions involving VAV1, encoding a truncated form of the VAV1 guanine nucleotide exchange factor important in T-cell receptor signaling. Fluorescence in situ hybridization studies identified VAV1 rearrangements in 10 of 148 PTCLs (7%). These were observed exclusively in PTCL, NOS (11%) and anaplastic large cell lymphoma (11%). In vitro, ectopic expression of a VAV1 fusion promoted cell growth and migration in a RAC1-dependent manner. This growth was inhibited by azathioprine, a clinically available RAC1 inhibitor. We also identified novel kinase gene fusions, ITK-FER and IKZF2-ERBB4, as candidate therapeutic targets that show similarities to known recurrent oncogenic ITK-SYK fusions and ERBB4 transcript variants in PTCLs, respectively. Additional novel and potentially clinically relevant fusions also were discovered. Together, these findings identify VAV1 fusions as recurrent and targetable events in PTCLs and highlight the potential for clinical sequencing to guide individualized therapy approaches for this group of aggressive malignancies.
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti‐HER2 targeted therapies
Gay, Laurie M. , Wang, Kai , Ali, Siraj M. , Chumsri, Saranya , Elvin, Julia A. , Bose, Ron , Vergilio, Jo‐Anne, Suh, James , Yelensky, Roman , Lipson, Doron , Chmielecki, Juliann , Waintraub, Stanley E., Leyland‐Jones, Brian , Miller, Vincent A. , Stephens, Philip J., Gay, Laurie M , Ross, Jeffrey S , Elvin, Julia A

Mayo Clinic

Cancer | June 10, 2016 | Volume: 122 | Issue: 17 | Pages: 2654-2662

10.1002/cncr.30102 | PMID 27284958 Get It

BACKGROUND Activating, nonamplification ERBB2 mutations ( ERBB2 mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), but are detected by DNA sequencing and may predict clinical responses to human epidermal growth factor receptor (HER2)‐targeted therapy. The authors queried 5605 advanced/metastatic breast cancers (mBC) to uncover the frequency of ERBB2 mut genomic alterations. Clinical responses to anti‐HER2 therapeutics were identified. METHODS DNA was extracted from 40 µm of formalin‐fixed paraffin‐embedded (FFPE) sections. Comprehensive genomic profiling (CGP) was used to evaluate up to 315 genes (592× mean coverage depth). Results were analyzed for base substitutions, short indels, copy number changes, and selected rearrangements. RESULTS Of 5605 cases, 698 (12.5%) featured ERBB2 alterations, including 596 (10.6%) ERBB2 amplifications ( ERBB2 amp) and 138 (2.4%) ERBB2 mut; 38 cases (0.7%) had co‐occurring ERBB2amp and ERBB2mut. ERBB2mut predominantly affected the kinase (124 cases; 90%) or extracellular (15 cases; 11%) domains. Both primary BC (52 cases; 38%) and metastatic site biopsies (86 cases; 62%) were found to harbor ERBB2 mut, which were distributed across carcinoma not otherwise specified (NOS) (69 cases; 50%), invasive ductal carcinoma (IDC) (40 cases; 29%), invasive lobular carcinoma (ILC) (27 cases; 20%), and mucinous mBC (2 cases; 1%). Genes commonly coaltered with ERBB2 were tumor protein 53 ( TP53 ) (49%); phosphatidylinositol 3‐kinase catalytic subunit alpha ( PIK3CA ) (42%); cadherin 1, type 1 ( CDH1 ) (37%); MYC (17%); and cyclin D1 protein ( CCND1 ) (16%). CDH1 mutations were enriched in ERBB2 mut mBC ( P <0.0006) and associated with recurrent mBC. Selected patients with ERBB2 mut, without ERBB2 amp, who responded to anti‐HER2 targeted therapies are presented herein. CONCLUSIONS Within this large series, 1.8% of cases harbored ERBB2 mut, which are undetectable by standard‐of‐care IHC or FISH tests. Metastatic BC driven by ERBB2 mut respond to anti‐HER2 targeted therapies, and expanding clinical trials designed to detect ERBB2 mut by CGP and optimize targeted treatments are warranted. Cancer 2016 . © 2016 American Cancer Society . Cancer 2016;122:2654–2662. © 2016 American Cancer Society.
FCGR3A/2A polymorphisms and diffuse large B‐cell lymphoma outcome treated with immunochemotherapy: a meta‐analysis on 1134 patients from two prospective cohorts
Ghesquières, Hervé , Larrabee, Beth R. , Link, Brian K. , Verney, Aurélie, Ketterer, Nicolas , Ansell, Stephen M. , Delarue, Richard, Fitoussi, Olivier , Peyrade, Frédéric, Molina, Thierry Jo , Novak, Anne J. , Tilly, Hervé , Salles, Gilles , Haïoun, Corinne , Slager, Susan L. , Maurer, Matthew J. , Habermann, Thomas M. , Doǧan, Ahmet , Cerhan, James R. , Link, Brian K , Salles, Gilles A

Mayo Clinic

Hematological Oncology | June 10, 2016 | Volume: 35 | Issue: 4 | Pages: 447-455

10.1002/hon.2305 | PMID 27282998 Get It

AbstractSingle nucleotide polymorphisms (SNPs) in FCγ‐receptor genes FCGR3A (rs396991) and FCGR2A (rs1801274) influence the affinity of the Fc portion of anti‐CD20 immunoglobulin G1 monoclonal antibody. Their roles in diffuse large B‐cell lymphoma (DLBCL) treated with rituximab in combination with anthracycline‐based chemotherapy remain controversial. To address this question, we genotyped FCGR2A and FCGR3A SNPs in two prospective DLBCL cohorts from Lymphoma Study Association trials (N = 554) and Iowa/Mayo Specialized Program Of Research Excellence (N = 580). Correlations with treatment response and hematological toxicity were assessed in Lymphoma Study Association. Correlation with event‐free survival (EFS) and overall survival (OS) was performed in both cohorts, followed by a meta‐analysis to increase power. Our study shows the absence of correlation between these SNPs and treatment response. Grades 3 and 4 febrile neutropenia during treatment was more frequently observed in FCGR3A VV (39%) than VF (29%) and FF (32%) carriers (p = 0.04). Our analysis for EFS and OS shows that FCGR3A was not associated with outcome. In a meta‐analysis using an ordinal model, FCGR2A (per R allele) was associated with a better EFS (hazard ratio = 0.87; 95%CI, 0.76–0.99; p = 0.04) and OS (hazard ratio = 0.86; 95%CI, 0.73–1.00; p = 0.05) which was not altered after adjustment for the International Prognostic Index. Overall, our data demonstrate that patients with DLBCL with the low‐affinity FCγRIIA RR had an unexpectedly better outcome than FCγRIIA H carriers. Whether rituximab efficacy is improved in FCγRIIA RR patients due a clearance reduction or other functions of FCγRIIA in DLBCL should be investigated (clinicaltrials.gov identifiers: NCT00135499, NTC00135499 NCT00140595, NCT00144807, NCT00144755, NCT01087424, and NCT00301821). Copyright © 2016 John Wiley & Sons, Ltd.
The effect of an automated point of care tool on diagnosis and management of childhood obesity in primary care
Gentile, Natalie, Cristiani, Valeria, Lynch, Brian , Wilson, Patrick M. , Weaver, Amy L. , Jacobson, Debra J., Chaudhry, Rajeev , Sriram, Swetha, Kumar, Seema , Lynch, Brian A, Rutten, Lila J, Rutten, Lila J. Finney

Mayo Clinic

Journal of Evaluation in Clinical Practice | June 10, 2016 | Volume: 22 | Issue: 6 | Pages: 962-968

10.1111/jep.12572 | PMID 27282887 Get It

AbstractBackgroundChildhood obesity is underdiagnosed in primary care practices. Our study aimed to compare rates of documentation of diagnosis of obesity and counselling for nutrition and physical activity at an academic primary care practice prior to and following implementation of a body mass index (BMI)‐based electronic point of care clinical reminder tool.MethodsWe performed a retrospective record review of children aged 2–18 years undergoing well child visits during any of three calendar years (2009, 2011 and 2013). The electronic clinical reminder tool was implemented in September 2010. Records of children with BMI > 95th percentile were electronically searched for terms of documentation of diagnosis of obesity and nutrition and physical activity counselling. Multivariable logistic regression models were used to adjust for potential patient and provider confounders.ResultsAmong those with BMI ≥ 95th percentile, there was a statistically significant increase in documentation of diagnosis of obesity (45.5% in 2009 vs. 52.4% in 2011; P < 0.001; adjusted odds ratio 1.36; 95% CI 1.13–1.65) and in counselling for physical activity and nutrition (66.8% in 2009 vs. 75.2% in 2011; P < 0.001; adjusted odds ratio 1.33; 95% CI 1.06–1.66) following implementation of the tool. Compared with 2011, there was no statistically significant increase in documentation of obesity (50.4%) or nutrition and physical activity counselling (77.9%) in 2013.ConclusionsThe implementation of a point of care clinical reminder tool was associated with improvement in documentation of diagnosis of obesity and counselling for nutrition and physical activity. Further studies are needed to determine the impact of these automated tools on weight outcomes in children.
Central retinal vein occlusion after plateletpheresis
Roddy, Gavin W. , Kreuter, Justin D. , Koh, Brian D. , Barkmeier, Andrew J.

Mayo Clinic

Transfusion | June 6, 2016 | Volume: 56 | Issue: 6 | Pages: 1258-1258

10.1111/trf.13419 | PMID 27264010 Get It

Automated Quantitative Computed Tomography Versus Visual Computed Tomography Scoring in Idiopathic Pulmonary Fibrosis
Jacob, Joseph , Bartholmai, Brian J. , Rajagopalan, Srinivasan, Kokosi, Maria , Nair, Arjun , Karwoski, Ronald A., Raghunath, Sushravya , Walsh, Simon , Wells, Athol U. , Hansell, David M., Bartholmai, Brian J

Mayo Clinic

Journal of Thoracic Imaging | June 4, 2016 | Volume: 31 | Issue: 5 | Pages: 304-311

10.1097/rti.0000000000000220 | PMID 27262146 Get It

Purpose: The aim of the study was to determine whether a novel computed tomography (CT) postprocessing software technique (CALIPER) is superior to visual CT scoring as judged by functional correlations in idiopathic pulmonary fibrosis (IPF). Materials and Methods: A total of 283 consecutive patients with IPF had CT parenchymal patterns evaluated quantitatively with CALIPER and by visual scoring. These 2 techniques were evaluated against: forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLco), carbon monoxide transfer coefficient (Kco), and a composite physiological index (CPI), with regard to extent of interstitial lung disease (ILD), extent of emphysema, and pulmonary vascular abnormalities. Results: CALIPER-derived estimates of ILD extent demonstrated stronger univariate correlations than visual scores for most pulmonary function tests (PFTs): (FEV1: CALIPER R 2=0.29, visual R 2=0.18; FVC: CALIPER R 2=0.41, visual R 2=0.27; DLco: CALIPER R 2=0.31, visual R 2=0.35; CPI: CALIPER R 2=0.48, visual R 2=0.44). Correlations between CT measures of emphysema extent and PFTs were weak and did not differ significantly between CALIPER and visual scoring. Intriguingly, the pulmonary vessel volume provided similar correlations to total ILD extent scored by CALIPER for FVC, DLco, and CPI (FVC: R 2=0.45; DLco: R 2=0.34; CPI: R 2=0.53). Conclusions: CALIPER was superior to visual scoring as validated by functional correlations with PFTs. The pulmonary vessel volume, a novel CALIPER CT parameter with no visual scoring equivalent, has the potential to be a CT feature in the assessment of patients with IPF and requires further exploration.
Effects of Smoking Status on Device Survival Among Individuals Undergoing Artificial Urinary Sphincter Placement
Godwin, Christina, Linder, Brian J. , Rivera, Marcelino , Ziegelmann, Matthew , Elliott, Daniel S. , Godwin, Christina A, Rivera, Marcelino E, Ziegelmann, Matthew J, Linder, Brian J

Mayo Clinic

American Journal of Men's Health | May 30, 2016 | Volume: 12 | Issue: 5 | Pages: 1398-1402

10.1177/1557988316651133 | PMID 27241681 Get It

Smoking is an established risk factor for wound complications. There is limited data on the impact of smoking on artificial urinary sphincter (AUS) outcomes. Thus, the aim of this study was to assess AUS device survival outcomes based on smoking status. From 1985 to 2014, 1,270 patients underwent AUS placement with 728 having smoking status available for review. Smoking status was categorized as never, prior, and active smokers. Kaplan−Meier analysis was performed to evaluate differences in survival, including overall device and erosion/infection−free survival. Hazard regression analysis was utilized to determine the association between smoking and device outcomes. Of the 728 patients in the study, 401 had a history of smoking with 41 active smokers and 360 never smokers at the time of AUS implant. When compared with nonsmokers, past smokers had a higher rate of hypertension and prior transient ischemic attack. Clinical comorbidities were similar between nonsmokers and active smokers. On univariate analysis, patient age, history of transient ischemic attack, diabetes, and coronary artery disease were significantly associated with infection/erosion rate, but prior or active smoking statuses were not. Likewise, when comparing smokers (past or active) with lifelong nonsmokers, there was no significant difference in 1- and 5-year overall device survival. There was no evidence for adverse AUS outcomes in current or past smokers compared with nonsmokers. Given the established risk of perioperative complications secondary to smoking, the recommendation should still be to counsel patients to quit prior to undergoing AUS placement. External validation of these findings is needed.
Psychosis or Obsessions? Clozapine Associated with Worsening Obsessive-Compulsive Symptoms
Leung, Jonathan G. , Palmer, Brian A. , Leung, Jonathan G

Mayo Clinic

Case Reports in Psychiatry | May 30, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-5

10.1155/2016/2180748 | PMID 27313938 Get It

One underrecognized adverse event of clozapine is the emergence or worsening of obsessive-compulsive symptoms (OCS). OCS, particularly violent thoughts, can be inaccurately described as psychosis and result in a misdiagnosis. We report a case of a 42-year-old man, initially diagnosed with schizoaffective, who was placed on clozapine for the management of “violent delusions.” However, clozapine led to a worsening of these violent thoughts resulting in suicidal ideation and hospitalization. After exploration of the intrusive thoughts and noting these to be egodystonic, clearly disturbing, and time consuming, an alternative diagnosis of obsessive-compulsive disorder (OCD) was made. Clozapine was inevitably discontinued resulting in a significant reduction of the intrusive thoughts without emergence of psychosis or adverse events. While an overlapping phenomenology between OCD and psychotic disorders has been described, clozapine and other antiserotonergic antipsychotics have been implicated with the emergence or worsening of OCS. Unique to our case is that the patient’s obsessions had been treated as psychosis leading to the inadequate treatment of his primary illness, OCD. This case highlights the potential for OCD to masquerade as a psychotic disorder and reminds clinicians that clozapine may worsen OCS.
The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas
Fang, Dong, Gan, Haiyun , Lee, Jeong‐Heon , Han, Jing, Wang, Zhiquan , Riester, Scott M. , Jin, Long , Chen, Jianji , Zhou, Hui , Wang, Jinglong , Zhang, Honglian , Bradley, Elizabeth W. , Ho, Thai H. , Bridge, Julia A. , Thibodeau, Stephen N. , Ördög, Tamás , Chen, Yue , Wijnen, André J. van , Oliveira, André M. , Xu, Rui-Ming , Zhang, Zhiguo , van Wijnen, Andre J, Fang, Dong, Yang, Na , Rubin, Brian P. , Westendorf, Jennifer J. , van Wijnen, Andre J , Ho, Thai , Bradley, Elizabeth W , Zhang, Zhiguo , Lee, Jeong-Heon , Wang, Zhiquan

Mayo Clinic

Science | May 27, 2016 | Volume: 352 | Issue: 6291 | Pages: 1344-1348

10.1126/science.aae0065 | PMID 27229140 Get It

A cancer-promoting histone protein Mutations in the chromatin protein histone H3 are found in a number of pediatric cancers. The lysine-36–to–methionine (K36M) “oncohistone” mutation is seen in almost all chondroblastomas. Fang et al. show that the K36M mutant histones inhibit the normal methylation of this same residue in wild-type H3 histones. They do so by interfering with the enzymes that normally methylate this residue. The altered chromatin methylation patterns alter the expression of known cancer-related genes and impart cancer-related characteristics to the chondrocyte cells. Science , this issue p. 1344